Diversity of Function Is Inherent in Matricellular Proteins: an Appraisal of Thrombospondin I

R current appreciation of the involvement of hrombospondin 1 (TSP1) 1 in diverse biological processes (Fig. 1; 1, 3, 25) extends far beyond the role initially attributed to the protein in platelet aggregation and coagulation. This diversity of function has led to considerable confusion in the literature and skepticism among scientists that a single protein can subserve such protean, sometimes conflicting, functions. In this Commentary I will attempt to show that the ability of matricellular proteins, as defined below, to interact with a wide range of both matrix proteins and cell surface receptors can explain the complex biological functions of TSP1 and resolve many of the controversies regarding its mode of action. A conclusion of this analysis is that, even if allowances are made for some errors in experimentation and interpretation, the majority of the reported functions of TSP1, divergent as they appear to be, are likely to be correct. The term "matricellular" is used in this analysis to refer to a group of modular, extracellular proteins whose functions are achieved by binding to matrix proteins as well as to cell surface receptors, or to other molecules such as cytokines and proteases that interact, in turn, with the cell surface. In addition to TSP1, this group is likely to include members of the tenascin protein family, SPARC/osteonectin and its relatives, and osteopontin. Although matricellular proteins can be associated with structural elements such as collagen fibrils or basement membranes, it is presumed that they do not contribute to the structural integrity of these elements. An association could, nevertheless, serve to sequester matricellular proteins, and provide a source of the proteins for subsequent recruitment to the cell surface. It should be noted that the distinction between structural matrix and matricellular proteins is not complete, since proteins such as fibronectin and laminin, which do serve as integral components of structural elements, also have adhesive functions and play biological roles that partially overlap those of matricellular proteins. Furthermore, matricellular proteins may participate in the formation of structural complexes under some circum-

[1]  P. Steeg,et al.  Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. , 1994, Cancer research.

[2]  P. Hogg Thrombospondin 1 as an Enzyme Inhibitor , 1994, Thrombosis and Haemostasis.

[3]  E. Chambaz,et al.  Distinct effects of thrombospondin-1 and CISP/thrombospondin-2 on adrenocortical cell spreading , 1994, Molecular and Cellular Endocrinology.

[4]  S. Schultz-Cherry,et al.  Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. , 1994, The Journal of biological chemistry.

[5]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[6]  M. Sandler,et al.  A novel protein interacts with the major transforming growth factor-beta responsive element in the plasminogen activator inhibitor type-1 gene. , 1994, The Journal of biological chemistry.

[7]  S. Suchard,et al.  Role of thrombospondin in mesangial cell growth: possible existence of an autocrine feedback growth circuit. , 1994, Kidney international.

[8]  V. Dixit,et al.  Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. , 1994, The American journal of pathology.

[9]  P. Bornstein,et al.  Modulation of thrombospondin expression during differentiation of embryonal carcinoma cells , 1994, Journal of cellular physiology.

[10]  G. Tuszynski,et al.  Matrix-bound thrombospondin promotes angiogenesis in vitro , 1994, The Journal of cell biology.

[11]  H. Krutzsch,et al.  Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin‐binding domain and synthetic peptides from the type I repeats of thrombospondin , 1993, Journal of cellular biochemistry.

[12]  O. Volpert,et al.  Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity , 1993, The Journal of cell biology.

[13]  M. Iruela-Arispe,et al.  Differential expression of thrombospondin 1, 2, and 3 during murine development , 1993, Developmental dynamics : an official publication of the American Association of Anatomists.

[14]  H. Erickson,et al.  Gene knockouts of c-src, transforming growth factor beta 1, and tenascin suggest superfluous, nonfunctional expression of proteins , 1993, The Journal of cell biology.

[15]  Josephine C. Adams,et al.  The thrombospondin family , 1993, Current Biology.

[16]  V. Dixit,et al.  High level thrombospondin 1 expression in two NIH 3T3 cloned lines confers serum- and anchorage-independent growth. , 1993, The Journal of biological chemistry.

[17]  Carol D. Laherty,et al.  Thrombospondin 1 and thrombospondin 2 are expressed as both homo- and heterotrimers. , 1992, The Journal of biological chemistry.

[18]  Y Ikawa,et al.  Mice develop normally without tenascin. , 1992, Genes & development.

[19]  K. Skorstengaard,et al.  Disulfides modulate RGD-inhibitable cell adhesive activity of thrombospondin , 1992, The Journal of cell biology.

[20]  C. Corless,et al.  Colocalization of thrombospondin and syndecan during murine development , 1992, Developmental dynamics : an official publication of the American Association of Anatomists.

[21]  F. W. Wolf,et al.  Characterization of mouse thrombospondin 2 sequence and expression during cell growth and development. , 1992, The Journal of biological chemistry.

[22]  P. Bornstein,et al.  Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. , 1991, The Journal of biological chemistry.

[23]  M. Iruela-Arispe,et al.  Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Prochownik,et al.  Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. , 1991, The Journal of clinical investigation.

[25]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Dixit,et al.  Induction of thrombospondin messenger RNA levels occurs as an immediate primary response to platelet-derived growth factor. , 1987, The Journal of biological chemistry.

[27]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[28]  P. Bornstein,et al.  Thrombospondins: structure and regulation of expression , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  P. Bornstein,et al.  Modulation of thrombospondin gene expression during osteoblast differentiation in MC3T3-E1 cells. , 1992, Bone.